– USA, MA – ImmunoMolecular Therapeutics, Inc., a clinical-stage company developing personalized therapies for autoimmune disease, today announced the appointment of Jonathan Rigby to its Board of Directors.
Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen variants known to play a strong role in autoimmune diseases.
“Jonathan brings a strong corporate development and drug development perspective to our team as we position our technology platform towards multiple autoimmune conditions,” said CEO, Dr. Nandan Padukone. “He is a great asset to the company as we complete Phase 1 studies in T1D, prepare for Phase 2 through early next year, and build our pipeline in celiac disease and other autoimmune diseases.”
About Jonathan Rigby
Mr. Rigby has three decades of experience building biopharmaceutical companies from early stages to IPO and acquisitions. He is currently President and Group CEO and a member of the Board of Immune Regulation Ltd, a company involved in developing novel treatments for autoimmune and allergic diseases. Previously, he established SteadyMed Therapeutics Inc, (NASDAQ IPO 2015, STDY), acquired by United Therapeutics (Nasdaq: UTHR) in 2018, and Zogenix, Inc. (NASDAQ IPO 2010, ZGNX). Before Zogenix, he worked at Aradigm Corp, a leader in the development of inhaled insulin, and held commercial and business development positions at Merck, Bristol Myers Squibb, and Phillips Medical.
Mr. Rigby currently serves on the Board of Directors of Thermalin Inc., and previously Xeris Pharmaceuticals (Nasdaq: XERS); and Chairman of CollPlant Biotechnologies, (Nasdaq: CLGN).
“I have a deep connection with autoimmune disease management, particularly type 1 diabetes, and am fascinated with the oral targeted drug approach of IM Therapeutics directed at genetic targets,” said Jonathan Rigby. “I am also impressed by the clinical progress the team has achieved with IMT-002 as a lead drug in a short period of time and in the midst of a pandemic.”
He holds a Bachelor of Science Degree, with Honors, in Biological Sciences from Sheffield University, UK, and an MBA from Portsmouth University, UK.
About IM Therapeutics
IM Therapeutics is a clinical-stage company developing personalized medicines for autoimmune diseases by creating oral medicines against human leukocyte antigen variants known to confer a high risk of disease. The Company’s technology platform develops small molecule drugs using in silico docking of millions of compounds into pockets of an HLA variant where self-antigens may bind to trigger autoimmunity. Selected drug hits are then optimized using proprietary structure-based design and activity screening with cell-based assays for the specificity of HLA inhibition. Lead drugs developed against an HLA variant have the ability to block a series of self-antigens and therefore the potential to treat several autoimmune indications related to a selected HLA. The Company is building a broad HLA-targeted pipeline in autoimmune disorders including type 1 diabetes, celiac disease, and lupus.
For more information: https://www.imtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
